Read by QxMD icon Read

early hepatocellular carcinoma

Xue Jing, Zibin Tian, Pujun Gao, Huashi Xiao, Xiaolong Qi, Yanan Yu, Xueli Ding, Lin Yang, Liang Zong
Chronic hepatitis B virus (HBV) infection remains one of the leading causes of hepatocellular carcinoma (HCC) globally. However, the mechanism underlying the mediation by HBV surface proteins (HBsAgs) of the early steps in the virus life cycle and following HCC development is unclear. β‑2‑glycoprotein I (β2GPI) specifically interacts with HBsAg and demonstrates high expression during the earliest stages of hepatitis B virus infection. In the present study, the assessment of HCC and adjacent tissues revealed that the levels of mRNA and protein of β2GPI were highly expressed in HBV‑related HCC...
June 19, 2018: Oncology Reports
Lu-Nan Qi, Bang-De Xiang, Fei-Xiang Wu, Jia-Zhou Ye, Jian-Hong Zhong, Yan-Yan Wang, Yuan-Yuan Chen, Zu-Shun Chen, Liang Ma, Jie Chen, Wen-Feng Gong, Ze-Guang Han, Yan Lu, Jin-Jie Shang, Le-Qun Li
To clarify the significance of circulating tumor cells (CTC) undergoing epithelial-mesenchymal transition (EMT) in hepatocellular carcinoma (HCC) patients, we used an advanced CanPatrol™ CTC-enrichment technique and in situ hybridization (ISH) to enrich and classify CTC from blood samples. 101 of 112 (90.18%) HCC patients were CTC-positive, even with early-stage disease. CTC were also detected in 2 of 12 hepatitis B virus (HBV) patients, both of whom had small HCC tumors detected within 5 months. CTC count ≥16 and mesenchymal-CTC (M-CTC) percentage ≥2% prior to resection were significantly associated with early recurrence, multi-intrahepatic recurrence, and lung metastasis...
June 18, 2018: Cancer Research
Shun Yamamoto, Shunsuke Kondo
Many clinical trials have been conducted with chemotherapies in patients with advanced hepatocellular carcinoma (HCC). However, few agents have shown efficacy. It is thought that the efficacy of some agents might have resulted from the heterogeneity of tumors, insufficient dosages due to liver cirrhosis, and post-therapy effects. In recent years, immune checkpoint inhibitors have shown promising clinical activity and safety in patients with advanced HCC. Areas covered: The authors provide an overview of chemotherapies used for the treatment of HCC, including ongoing trials...
June 18, 2018: Expert Opinion on Pharmacotherapy
Chuan Zhao, Mei Wang, Yu Liu, Yongjuan Liang, Li Han, Che Chen
Context: Previous studies have demonstrated that 3'-azido-3'-deoxythymidine (AZT) and arsenic trioxide (As2 O3 ), traditional chemotherapy agents, can synergically inhibit the growth of hepatocellular carcinoma cells. However, the molecular mechanisms underlying As2 O3 and AZT anti-hepatoma activity are unknown. Objective: This study aimed to investigate the role of early growth response protein 1 (Egr-1) in the process of As2 O3 combined with AZT inhibiting proliferation and inducing apoptosis of human hepatocellular carcinoma HepG2 cells, and explore the possible mechanism...
2018: OncoTargets and Therapy
Béla Hunyady, Margit Abonyi, Zsuzsanna Gerlei, Judit Gervain, Gábor Horváth, Viktor Jancsik, Gabriella Lengyel, Erzsébet Makkai, Alajos Pár, Zoltán Péter, Margit Pusztay, Pál Ribiczey, László Rókusz, Christoph Sarrazin, Ferenc Schneider, Simone Susser, Ferenc Szalay, István Tornai, Anna Tusnádi, Eszter Újhelyi, Klára Werling, Mihály Makara
Aim of the study: Combination of ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin (3DDA±RBV) therapy is shown to be effective in HCV genotype 1 (GT1) infected patients. However, sparse data exist in patients who failed previous boceprevir or telaprevir based therapies. Real life efficacy and safety of this combination were evaluated in HCV GT1b infected patients (mostly cirrhotics) with compensated liver disease who failed previous boceprevir or telaprevir based therapies more than a year before...
June 2018: Clinical and Experimental Hepatology
Pavan Tenneti, Mitesh J Board, Hani M Babiker
The standard of care for early hepatobiliary cancers (HBC) includes surgical resection. Liver transplantations or locoregional therapies are beneficial in early hepatocellular carcinoma (HCC) under certain circumstances. Systemic treatments have some benefit in advanced HBC, though long-term prognosis remains poor. We evaluated the role of oncolytic viruses in the treatment of HBCs through a systematic literature review. The recombinant vaccinia virus JX-594 improved median survival in patients with local/metastatic HCC more strongly at high dose than at low dose (14...
June 14, 2018: Immunotherapy
Manar A Elhinnawi, Rafat M Mohareb, Hanaa M Rady, Wagdy K B Khalil, Mervat M Abd Elhalim, Gamal A Elmegeed
A series of pregnenolone derivatives were synthesized and assessed for anti-cancer activity against hepatocellular carcinoma cell line (HepG2). The synthesized hetero-steroids (compounds 3, 4, 5, 6, 7, 8a and 8b) were evaluated for their cytotoxic activities using MTT (3-(4,5-Dimethylthiazol-2-yl)- 2,5-diphenyltetrazolium bromide) assay. Apoptotic activity was assessed using dual acridine orange/ethidium bromide staining method and DNA fragmentation assay. Pro-apoptotic genes (Bax and Bak) and anti-apoptotic genes (Bcl-2 and Bcl-xL) were analyzed using quantitative real time PCR...
June 10, 2018: Journal of Steroid Biochemistry and Molecular Biology
Preithy Uthamalingam, Ashim Das, Arunanshu Behra, Naveen Kalra, Yogesh Chawla
Background and objectives: Histopathological distinction of various nodular lesions in liver with sufficient sensitivity and specificity is a challenge even in an expert set up. The panel of immunohistochemical markers composed of glutamine synthetase (GS), Glypican3 (GPC3) and heat shock protein 70 (HSP70) was recommended by the International Consensus Group for Hepatocellular Neoplasia group for the differentiation of high grade dysplastic nodule and early hepatocellular carcinoma (HCC)...
June 2018: Journal of Clinical and Experimental Hepatology
Kwang Hoe Kim, Soo-Youn Lee, Heeyoun Hwang, Ju Yeon Lee, Eun Sun Ji, Hyun Joo An, Jin Young Kim, Jong Shin Yoo
PURPOSE: Alpha-fetoprotein (AFP) is a widely used serological marker that is associated with hepatocellular carcinoma (HCC). Although the level of AFP is increased in HCC, its sensitivity for diagnosis is poor because AFP levels are also increased in liver diseases. Changes in glycoform, especially fucosylation, have been reported to be associated with the development of HCC. EXPERIMENTAL DESIGN: We introduced the monitoring of fucosylated glycopeptides by liquid chromatography (LC)-mass spectrometry (MS) combined with immunoprecipitation, where glycan-cleaved fragments with an amino acid sequence were used as transitions...
June 11, 2018: Proteomics. Clinical Applications
Fabian Finkelmeier, Georg Dultz, Kai-Henrik Peiffer, Bernd Kronenberger, Franziska Krauss, Stefan Zeuzem, Christoph Sarrazin, Johannes Vermehren, Oliver Waidmann
Background and Aims: The aim of the study was to evaluate the risk of hepatocellular carcinoma (HCC) development after treatment with direct-acting antivirals (DAAs) and to compare HCC occurrence in these patients with that among patients treated with interferon (IFN)-based therapies. Methods: We analyzed a large cohort with chronic hepatitis C virus patients for the onset of new HCC after DAA treatment. A historical IFN-treated cohort was investigated for comparison...
May 2018: Liver Cancer
Kibo Nam, Maria Stanczak, Andrej Lyshchik, Priscilla Machado, Yuko Kono, Flemming Forsberg, Colette M Shaw, John R Eisenbrey
Quantitative 2D and 3D contrast-enhanced ultrasound (CEUS) was assessed to evaluate early transarterial chemoembolization (TACE) treatment response. Seventeen patients scheduled for TACE for the treatment of hepatocellular carcinoma participated in the study. 2D and 3D CEUS were performed for each patient at three time points: prior to TACE, 1-2 weeks post TACE, and 1 month post TACE. Peak-intensities of the tumor and surrounding liver tissue were calculated from 2D and 3D data before and after TACE and used to evaluate tumor treatment response...
May 2018: Biomedical Physics & Engineering Express
Fangqiang Wei
BACKGROUND: Increasing global life expectancy has resulted in a greater demand for cancer surgery in aged patients. However, whether extreme age causes poorer clinical outcomes remains unclear. This meta-analysis aimed to evaluate the impact of extreme age (≥80 years) on outcomes in patients after liver cancer surgery. METHODS: A systematic search was performed to enrol relevant studies. Data were analysed using fixed-effects or random-effects models. Eight retrospective studies involving 253 participants older than 80 years were included...
June 9, 2018: ANZ Journal of Surgery
Jingjing Jiao, Gordon P Watt, Heather L Stevenson, Tiffany L Calderone, Susan P Fisher-Hoch, Yuanqing Ye, Xifeng Wu, John M Vierling, Laura Beretta
Telomerase reverse transcriptase ( TERT ) mutation is the most frequent genetic alteration in hepatocellular carcinoma (HCC). Our aims were to investigate whether TERT mutations can be detected in circulating cell-free DNA (cfDNA) of patients with HCC and/or cirrhosis and characterize clinical parameters associated with these mutations. We retrieved data on TERT C228T and C250T promoter mutations in 196 HCCs from The Cancer Genome Atlas. We measured these TERT mutations in plasma cfDNA in 218 patients with HCC and 81 patients with cirrhosis without imaging evidence of HCC...
June 2018: Hepatology Communications
Q He, J J Jiang, Y X Jiang, W T Wang, L Yang
BACKGROUND: For cancer patients, health-related quality of life (HRQoL) is as important as other key outcomes, such as overall survival and tumor-free survival. Liver transplantation (LT), resection, and radiofrequency ablation (RFA) are 3 radical therapies for hepatocellular carcinoma (HCC) that result in similar survival. The main objective of this study was to assess and compare long-term HRQoL scores for patients with early-stage (tumor diameter ≤3 cm) HCC after LT, resection, or RFA...
June 2018: Transplantation Proceedings
Y Goto, N Shirahama, S Sasaki, R Kawahara, H Sakai, H Ishikawa, T Hisaka, T Ogata, M Yasunaga, Y Akagi, H Tanaka, K Okuda
BACKGROUND: Some literature has reported on endovascular treatment for very early hepatic artery stenosis (HAS; within 2 weeks after liver transplantation, and has deemed endovascular treatment to be a contraindication because out of serious complications associated with the procedure. We report on 2 cases of very early HAS successfully treated with endovascular treatment after living-donor liver transplantation (LDLT). CASE 1: A 54-year-old woman underwent LDLT with a left liver graft...
June 2018: Transplantation Proceedings
Xinmei Wang, Kwang Joo Kwak, Zhaogang Yang, Aili Zhang, Xiaoli Zhang, Rachael Sullivan, Dan Lin, Robert L Lee, Carlos Castro, Kalpana Ghoshal, Carl Schmidt, L James Lee
Hepatocellular carcinoma (HCC) remains one of the major causes of cancer related deaths. Although ultrasonography (US), computed tomography (CT) and/or high-cost magnetic resonance imaging (MRI) have been shown to improve early detection of liver cancer and mortality rates in high-risk individuals, such imaging based methods are limited by high rates of false positivity leading to unnecessary patient anxiety and invasive procedures. Complementary blood biomarkers could increase the accuracy of early detection...
2018: PloS One
Neehar D Parikh, Vincent D Marshall, Michael Green, Theodore S Lawrence, Nataliya Razumilava, Dawn Owen, Amit G Singal, Mary Feng
INTRODUCTION: For early-stage hepatocellular carcinoma (HCC) patients, ablative strategies are potentially curative treatment options. Stereotactic body radiotherapy (SBRT) has emerged as a promising ablative therapy, although its comparison with radiofrequency ablation (RFA) remains confined to a single institution retrospective review. We sought to characterize the comparative outcomes and cost between the two treatment strategies. METHODS: We conducted a secondary analysis of the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database (2004-2011) and identified adult patients with stage I or II HCC and treated with RFA or SBRT as the initial treatment within 6 months of diagnosis...
June 7, 2018: Journal of Medical Imaging and Radiation Oncology
Eva Braunwarth, Stefan Stättner, Margot Fodor, Benno Cardini, Thomas Resch, Rupert Oberhuber, Daniel Putzer, Reto Bale, Manuel Maglione, Christian Margreiter, Stefan Schneeberger, Dietmar Öfner, Florian Primavesi
Background: Owing to remarkable improvements of surgical techniques and associated specialities, liver surgery has become the standard of care for hepatocellular carcinoma and cholangiocarcinoma. Although applied with much greater safety, hepatic resections for primary liver tumours remain challenging and need to be integrated in a complex multidisciplinary treatment approach. Methods: This literature review gives an update on the recent developments regarding basics of open and laparoscopic liver surgery and surgical strategies for primary liver tumours...
2018: European Surgery: ACA: Acta Chirurgica Austriaca
Hyunsoo Kim, Areum Sohn, Injoon Yeo, Su Jong Yu, Jung-Hwan Yoon, Youngsoo Kim
BACKGROUND: Lens culinaris agglutinin-reactive fraction of α-fetoprotein (AFP-L3) is a serum biomarker for hepatocellular carcinoma (HCC). AFP-L3 is typically measured by liquid-phase binding assay (LiBA). However, LiBA does not always reflect AFP-L3 concentrations because of its low analytical sensitivity. Thus, we aimed to develop an analytically sensitive multiple reaction monitoring-mass spectrometry (MRM-MS) assay to quantify AFP-L3 in serum. METHODS: The assay entailed the addition of a stable isotope-labeled internal standard protein analog, the enrichment of AFP using a monoclonal antibody, the fractionation of AFP-L3 using L...
June 6, 2018: Clinical Chemistry
Margaret A Hill, William B Alexander, Bing Guo, Yasutaka Kato, Krushna Chandra Patra, Michael R O'Dell, Matthew N McCall, Christa L Whitney-Miller, Nabeel Bardeesy, Aram F Hezel
Intrahepatic cholangiocarcinoma (iCCA) is a primary liver cancer epidemiologically linked with liver injury which has poorly understood incipient stages and lacks early diagnostics and effective therapies. While iCCA is conventionally thought to arise from the biliary tract, studies have suggested that both hepatocytes and biliary cells (cholangiocytes) may give rise to iCCA. Consistent with the plasticity of these cell lineages, primary liver carcinomas exhibit a phenotypic range from hepatocellular carcinoma (HCC) to iCCA with intermediates along this spectrum...
June 5, 2018: Cancer Research
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"